“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
نویسندگان
چکیده
We describe the case of an early-onset Parkinson's disease (PD) patient, suffering from a severe and unusual dyskinetic gait pattern, earlier described as "Silly walk." On presentation, the 58-year-old patient showed a painful, bizarre dyskinetic gait disorder, resulting in a significantly impairment of her social life. We developed an individual conservative training method for the patient, using "Cueing mechanisms," well known for treatment of Freezing in PD, to overcome her dyskinetic gait pattern. An impressive improvement was seen after the use of visual and acousting cues. We, therefore, conclude that it might be important for PD patients to recognize these specific movement abnormalities and start early with individualized training methods. Moreover, especially for "Silly walk" individuals, "Cueing" strategies can be an important new basis of conservative training methods for dyskinesia.
منابع مشابه
Neurodegenerative Disease Parkinson’s Disease
Oral levodopa remains the most effective symptomatic drug for Parkinson’s disease (PD); however, its long-term use is limited by the emergence of motor fluctuations and involuntary movements, particularly in young-onset patients. A growing number of pre-clinical and clinical studies suggest that non-physiological pulsatile stimulation of striatal dopamine (DA) receptors induced by the use of sh...
متن کاملOp-brai150098 1658..1666
Dopaminergic signalling in the striatum contributes to reinforcement of actions and motivational enhancement of motor vigour. Parkinson’s disease leads to progressive dopaminergic denervation of the striatum, impairing the function of cortico-basal ganglia networks. While levodopa therapy alleviates basal ganglia dysfunction in Parkinson’s disease, it often elicits involuntary movements, referr...
متن کاملOp-brai150098 1..9
Dopaminergic signalling in the striatum contributes to reinforcement of actions and motivational enhancement of motor vigour. Parkinson’s disease leads to progressive dopaminergic denervation of the striatum, impairing the function of cortico-basal ganglia networks. While levodopa therapy alleviates basal ganglia dysfunction in Parkinson’s disease, it often elicits involuntary movements, referr...
متن کاملLevodopa-induced Dyskinesias and Their Management N Epidemiology
Following a period of stable response to dopaminergic medication (the “honeymoon” period), Parkinson’s disease (PD) patients gradually develop two progressive clinical phenomena requiring changes in the clinical management: motor fluctuations and dyskinesias. These two phenomena are intrinsically interconnected, but often require opposite treatment attitudes, because increases of dopaminergic t...
متن کاملDifferent Dyskinesias in Parkinson’s Disease and Their Relationship to Levodopa
Levodopa is the principal agent in the treatment of Parkinson’s disease (PD). Unfortunately the therapeutic benefits are optimal only in the early stages of the disease, with long-term use associated with motor complications such as levodopa-induced dyskinesia (LID). Risk factors associated with the development of LID are generally accepted to involve the degree of dopamine (DA) denervation in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 7 شماره
صفحات -
تاریخ انتشار 2016